Israeli clinical-stage immunotherapy company Enlivex Therapeutics will buy Bitcoin as a reserve asset

avatar
Foresight News
11 hours ago
This article is machine translated
Show original

According to Foresight News , Enlivex Therapeutics, an Israeli clinical-stage immunotherapy company, announced that its board of directors approved the purchase of up to $1 million in Bitcoin as part of its cash management strategy. The company is listed on the Nasdaq in the United States (code: ENLV), and CEO Oren Hershkovitz said that with the growth of Bitcoin demand and acceptance, coupled with the recent approval of Bitcoin ETFs and support from institutional investors, the company believes that Bitcoin can serve as a strong asset reserve, providing value storage and anti-inflation functions.

Source
Disclaimer: The content above is only the author's opinion which does not represent any position of Followin, and is not intended as, and shall not be understood or construed as, investment advice from Followin.
Like
Add to Favorites
Comments